STRO Stock Forecast: Sutro Biopharma, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$8.60
−1.38% on the day

The median 12-month analyst price target for Sutro Biopharma, Inc. is $49. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 56 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$142.8M
Ticker Nerd rank
56/ 100
Median analyst target
$49
Analysts covering
14
Revenue$9.8M−84.6% y/y
Operating income−$29.7M
Net income−$38.5M
Free cash flow−$38.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.4%
1M
−25.5%
YTD
−25.7%
1Y
+1.2%
From 52W high
−79.0%
From 52W low
+17.8%
$7
$41
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Sutro Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
56/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Accruals
78
Value
73
Quality
47
Revisions
44
Momentum
41
Volatility
37
Issuance
6

Growth (86): Sales and profits are climbing, and climbing faster than before.

Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

STRO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on STRO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26STROHigh $61Median $49Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
13
Buy
0
Hold
1
Sell
$10
Low
$49
Median
$61
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Nov 2026BarclaysMaintainsOverweight$56 → $57
15 Oct 2026WedbushReiteratesOutperform$60
13 Aug 2026CitizensMaintainsMarket Outperform$41 → $34
13 Aug 2026WedbushReiteratesOutperform$60
11 June 2026Truist SecuritiesAssumesBuy$50
28 May 2026BarclaysInitiatesOverweight—
15 May 2026HC Wainwright & Co.MaintainsBuy—
15 May 2026Leerink PartnersMaintainsOutperform—
15 May 2026WedbushUpgradeOutperform—
30 Apr 2026MizuhoInitiatesOutperform—
23 Apr 2026CitizensMaintainsMarket Outperform—
17 Apr 2026CitizensMaintainsMarket Outperform—
7 Apr 2026Leerink PartnersInitiatesOutperform—
25 Mar 2026Deutsche BankMaintainsBuy—
24 Mar 2026HC Wainwright & Co.UpgradeBuy—
24 Mar 2026Wells FargoUpgradeOverweight—
20 Jan 2026CitizensUpgradeMarket Outperform—
22 Dec 2025HC Wainwright & Co.MaintainsNeutral—
12 Aug 2025Wells FargoMaintainsEqual-Weight—
16 June 2025Piper SandlerUpgradeOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for STRO.

Market Radar

This page is one stock. Monday covers all of them.

STRO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

STRO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Sutro Biopharma, Inc. returned +1.2% against +6.9% for the S&P 500, dividends included.

STRO vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26STROS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

STRO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.2×

Cheaper than 34% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−37.2%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Sutro Biopharma, Inc. has a market value of $142.8M and an enterprise value of $10.3M.

  • Revenue in the twelve months to 30 June 2026: $45.7M. The latest quarter shrank 84.6% year on year.

  • Net income over the same four quarters: −$180.6M, a −395.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$145.6M.

  • Shares outstanding: 16.6M.

  • Sutro Biopharma, Inc. employs 129 people — $354K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

STRO and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
STROSutro Biopharma, Inc.$142.8M56
ABEOAbeona Therapeutics, Inc.$138.1M53
ELDNEledon Pharmaceuticals, Inc.$144.6M29
ALXOALX Oncology Holdings, Inc.$137.0M44
BBOTBridgebio Oncology Therapeutics, Inc.$145.1M22
PALIPalisade Bio, Inc.$146.4M19
PRQRProQR Therapeutics NV$146.8M47

Take a look at STRO’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Sutro Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about STRO

What is the STRO stock price forecast for 2026-2027?

The median 12-month analyst price target for Sutro Biopharma, Inc. is $49, with estimates ranging from $10 to $61. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is STRO stock a buy right now?

Of the 14 analysts covering Sutro Biopharma, Inc., 13 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Sutro Biopharma, Inc. 56 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank STRO?

As at 21 Nov 2026, Sutro Biopharma, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will STRO stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts is $49, and Ticker Nerd's factor model ranks Sutro Biopharma, Inc. 56 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the STRO stock forecast for 2030?

No analyst covering Sutro Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STRO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $61 over the next 12 months.

How has STRO stock performed over the past year?

Sutro Biopharma, Inc. returned +1.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Sutro Biopharma, Inc. do?

Sutro Biopharma Inc. is a clinical-stage biotechnology company focused on developing next-generation cancer therapeutics. The company designs and advances antibody-drug conjugates, including site-specific, single-payload, dual-payload, and immunostimulatory formats, using its proprietary XpressCF and XpressCF+ platforms.

Company

About Sutro Biopharma, Inc.

Sutro Biopharma Inc. is a clinical-stage biotechnology company focused on developing next-generation cancer therapeutics. The company designs and advances antibody-drug conjugates, including site-specific, single-payload, dual-payload, and immunostimulatory formats, using its proprietary XpressCF and XpressCF+ platforms. These technologies support the discovery, development, and manufacture of biologic drug candidates intended for oncology and other immune-related diseases. Sutro Biopharma’s work centers on creating precisely engineered therapies for solid tumors and hematologic cancers, while also supporting collaborative research and development efforts with pharmaceutical partners. Headquartered in South San Francisco, California, Sutro Biopharma plays a specialized role in the biopharmaceutical market by combining protein engineering, drug conjugation, and therapeutic development within a single platform-driven approach.

CEO Ms. Jane Chung R.Ph. · 129 employees · United States · https://www.sutrobio.com